BMY Bristol-Myers Squibb Co

56.47
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 late breaker at ASCO June 5, 2017. Abstract LBA8507.
Opdivo + Yervoy
Malignant pleural mesothelioma (MPM)
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017. Abstract 3003.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo
(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)
Phase 3 first overall survival (OS) positive data released April 3, 2017
CM - 067 Opdivo in combination with Yervoy
Melanoma
Phase 3 data released January 19, 2017.
Opdivo - ONO-4538-12
Gastric cancer
Phase 2 data due 1H 2017.
CM-568 - Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2018.
CM-651 – Opdivo + Yervoy
First-line Head and Neck Cancer
Phase 3 data due 2H 2018.
CM-602 – Opdivo + Elo + SOC
Myeloma
Phase 3 data due 1H 2017.
CM-511 – Opdivo + Yervoy
First-line Melanoma
Phase 3 data due 2H 2017.
CM-459 – Opdivo
First-line Hepatocellular carcinoma (HCC) - cancer
Phase 3 data due 1H 2018.
CM-451 – Opdivo + Yervoy
First-line Small cell lung cancer (SCLC)
Phase 3 data due 1H 2018.
CM-331– Opdivo
Second-line Small cell lung cancer (SCLC)
Phase 3 data due 2H 2018.
CM-238 – Opdivo (Adjuvant)
Melanoma
Phase 3 data due 1H 2018.
CM-227 – Opdivo + Yervoy
First-line Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2017.
CM-214 – Opdivo + Yervoy
First-line Renal cell carcinoma (RCC)
Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-143 – Opdivo
Second-line Glioblastoma (GBM) cancer
Phase 3 data due 1H 2017.
CM-140 – Opdivo
Second-line Non-Hodgkin's Lymphoma (NHL)
Phase 3 data due 1H 2018.
CM-078 – Opdivo
Second-line Non-small cell lung cancer (NSCLC)
Phase 2 data due 1H 2018.
CM-548 - Opdivo+SOC
First-line Glioblastoma (GBM) cancer
Urothelial Carcinoma - Bladder cancer
Opdivo (nivolumab)
Bladder cancer

Latest News

  1. Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
  2. Bristol-Myers NASH drug reduces liver fat in midstage study
  3. Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
  4. Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
  5. Is Bristol-Myers Prepping To Outdo Itself In Immuno-Oncology?
  6. Bristol-Myers Squibb Co: Buy the Dip?
  7. Bristol-Myers 'Holding Up Better,' But Dow's Merck Still Gouging Share
  8. The 4 Best Dividend Stocks in Pharmaceuticals
  9. Bristol-Myers and Nordic Ink Biomarker Collaboration Deal
  10. Exelixis, Inc.: Time to Move On?
  11. Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology
  12. Top Research Reports for Alphabet, Amgen & Lowe's
  13. Biogen to License Alzheimer Candidate from Bristol-Myers
  14. Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology
  15. Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : April 07th, 2017 (record date) : By the numbers : April 14, 2017
  16. Could Bristol's Drug Help Biogen Take AbbVie In Alzheimer's?
  17. Morgan Stanley Ups Incyte Target to $150
  18. Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug
  19. Bristol-Myers to license two drugs to Biogen, Roche
  20. Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops